MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2022 International Congress

    Does autosomal recessive Parkinson’s Disease behave as “Brain-first” subtype?

    B. Soydas-Turan, G. Yalcin-Cakmakli, B. Volkan-Salanci, E. Lay-Ergun, B. Elibol (Ankara, Turkey)

    Objective: The aim of this study is to explore whether monogenic PD (due to parkin or DJ-1 homozygous mutations) can be subtyped as "brain-first" by…
  • 2022 International Congress

    Fragile X Associated Tremor and Ataxia Syndrome (FXTAS) presents with widespread reactive gliosis and white-matter specific astrocyte degeneration

    B. Dufour, V. Martínez-Cerdeño (Sacramento, USA)

    Objective: We will characterize neuropathological alterations of astrocytes in different regions of the FXTAS brain. Background: FXTAS is a progressive neurodegenerative disorder that occurs in…
  • 2022 International Congress

    SETTING UP A PEDIATRIC DEEP BRAIN STIMULATION UNIT

    J. Ferrero-Turrión, A. Salazar-Villacorta, A. Bescos, G. Español, L. Ispierto, R. Alvarez, M. Tardáguila, J. Muñoz, L. Ventura-Expósito, B. Pérez-Dueñas (Barcelona, Spain)

    Objective: Describe our 2-year experience establishing a pediatric deep brain stimulation (pDBS) service in a tertiary hospital and report our outcomes. Background: DBS is a…
  • 2022 International Congress

    Cognition in Huntington’s Disease

    A. Sethi, O. Kaczmarek, S. Baek, B. Bumstead, M. Buhse, M. Zarif, M. Gudesblatt (Patchogue, USA)

    Objective: Explore the cognitive profile of patients with Huntington’s Disease (HD) using a digital cognitive battery Background: Huntington’s Disease (HD) is a relentlessly progressive neurodegenerative…
  • 2022 International Congress

    Short and long-term Impact of Covid-19 Pandemic on motor and non-motor symptoms in Leucine-rich repeat kinase2 (LRRK2) associated Parkinson’s disease

    A. Nasri, S. Mrabet, Y. Abida, A. Souissi, A. Gharbi, A. Gargouri, I. Kacem, R. Gouider (Tunis, Tunisia)

    Objective: To determine short and long-term impact of COVID-19 on motor(MS) and non-motor(NMS) symptoms among Tunisian PD patients according to Leucine-rich repeat kinase2 (LRRK2)-carrying status.…
  • 2022 International Congress

    Connectivity matrices for differentiating voluntary stopping states and involuntary freezing states in Parkinson’s disease

    D. Salgado, A. Pineda, C. Alves, R. Carra, F. Rodrigues, M. Souza, R. Cury (São Paulo, Brazil)

    Objective: The present study aims to demonstrate a possible application of the analysis of functional brain connectivity from brain connectivity matrices. Specifically, we aim to: - Differentiate…
  • 2022 International Congress

    Diagnostic accuracy of dopamine SPECT in degenerative parkinsonism compared to neuropathological diagnosis.

    A. Hastings, H. Morris, Z. Jaunmuktane, T. Warner, E. de Pablo-Fernandez (London, United Kingdom)

    Objective: To evaluate diagnostic accuracy of dopamine SPECT against neuropathological diagnosis in a large cohort of patients with parkinsonism. Background: Diagnosis of parkinsonian syndromes remains…
  • 2022 International Congress

    Studying Care Patterns and Support Preferences Among People Living with Parkinson’s Disease

    C. Pearson, M. Feeney, A. Willis, N. Yarab, R. Dolhun, V. Todaro, S. Rosenfeld (Chicago, USA)

    Objective: To understand health care utilization among Medicare beneficiaries living with Parkinson’s Disease (PD) and how care patterns differ across demographic groups. Background: Optimal care…
  • 2022 International Congress

    LRRK2 Inhibition by BIIB122: Trial designs for two efficacy and safety studies in Parkinson’s disease patients with and without LRRK2 mutations (Lighthouse and Luma)

    J. Shirvan, D. Jennings, P. Wang, R. Maciuca, S. Sahu, F. Sedarati, A. Kay, K. Fraser, S. Huntwork-Rodriguez, M. Yang, M. Levee, P. Chin, T. Dam (Cambridge, USA)

    Objective: Describe Luma and Lighthouse, two studies that investigate efficacy and safety of BIIB122, a LRRK2 inhibitor. Background: Increased LRRK2 kinase activity has been linked…
  • 2022 International Congress

    Feasibility of using ENROLL-HD for health services research: Evaluation of delays in Huntington’s Disease (HD) Diagnosis

    A. Mendizabal, S. Perlman, Y. Bordelon (LOS ANGELES, USA)

    Objective: To describe social and structural determinants of health of HD patients and to evaluate the feasibility of using this dataset for health services research.…
  • « Previous Page
  • 1
  • …
  • 103
  • 104
  • 105
  • 106
  • 107
  • …
  • 153
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley